Subscribe To
Nanobiotix surges on commercialization deal with j&j's janssen for cancer therapeutic
French biotechnology company Nanobiotix has entered into an agreement with J&J's wholly-owned medical research and pharmaceutical arm Janssen to licen...
July 10, 2023, 1:11 pm
Quanterix (qtrx) advances in alzheimer's diagnosis with lucentad
Quanterix (QTRX) LucentAD biomarker blood test aims to assist healthcare providers in evaluating patien...
July 10, 2023, 12:30 pm
Novartis (nvs) entresto patent faces setback, stock down
Novartis (NVS) faces a setback in the patent litigation with respect to the blockbuster heart disease d...
July 10, 2023, 12:30 pm
Helen of troy cut inventory and improved working capital, beating earnings forecast
Helen of Troy shares jumped over 15% in early trading on Monday after reporting first quarter earnings and revenue that exceeded analyst estimates, de...
July 10, 2023, 12:20 pm
Dolby (dlb) stock gains 21.7% ytd: will the trend continue?
Dolby's (DLB) performance benefits from the increasing adoption of Dolby Atmos, Dolby Vision and new imaging p...
July 10, 2023, 11:00 am
Here's why alkermes (alks) is a great 'buy the bottom' stock now
Alkermes (ALKS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this tec...
July 10, 2023, 11:00 am
Transcode therapeutics inc. (rnaz) may find a bottom soon, here's why you should buy the stock now
TransCode Therapeutics Inc. (RNAZ) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In a...
July 10, 2023, 11:00 am
Shareholders in these 2 stocks got nasty surprises monday
Markets were generally slightly higher by midmorning on Monday. FMC warned that its quarterly financial results wouldn't be as strong as antici...
July 10, 2023, 10:48 am
Atossa therapeutics provides update on phase 2 breast density trial enrollment
Atossa Therapeutics Inc (NASDAQ:ATOS) announced that 170 patients have been enrolled across its ongoing...
July 10, 2023, 10:37 am
Axsome (axsm) doses first patient in late-stage adhd study
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for trea...
July 10, 2023, 10:15 am
Hca healthcare reports data breach that exposed patient information
HCA Healthcare Inc. HCA, -1.01% said Monday that patient names, phone numbers, dates of birth, appointm...
July 10, 2023, 8:48 am
Column: oil investors less bearish after saudi output cut extended: kemp
Portfolio investors tip-toed back into crude oil as Saudi Arabia extended its unilateral production cut for at least another month, dissi...
July 10, 2023, 8:31 am
Sagimet biosciences sets ipo terms, to raise up to about $80 million
Sagimet Biosciences Inc. SGMT, disclosed Monday terms for its initial public offering, in which the California-based biopharmaceutical company focused...
July 10, 2023, 7:05 am
Boohoo plans to take revolution beauty row to regulator
The spat between Boohoo Group PLC (AIM:BOO) and Revolution Beauty Group PLC, the AIM-listed retailer, i...
July 10, 2023, 6:19 am
Eli lilly: patients get skinnier, profits get fatter
Eli Lilly has seen a massive ramp-up in its diabetes, or better said weight loss, drug Mounjaro. Investors continue to price in further advancements o...
July 10, 2023, 4:49 am
Zephyr energy “fully expects” to deliver production test for state 36-2 well
Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) told investors that it fully expects to deliver a production test of the State 36-2 LNW-CC well, at the Para...
July 10, 2023, 2:59 am
Gold price forecast: uncertain us jobs data raises doubts on rate hike path
Gold traders to closely monitor upcoming CPI data as a significant miss could impact expectations of a July rate hike by the Federal Reserve....
July 10, 2023, 2:17 am
General dynamics is poised for growth and way too cheap
General Dynamics is well-positioned for growth due to demand for its defense hardware and expected growth in munitions and supply chain improvements. ...
July 9, 2023, 12:31 pm
Mirum: must watch biotech on release of results from embark study
Results from the phase 2b EMBARK study, which is using LIMVARLI for the treatment of patients with bili...
July 9, 2023, 11:01 am
Sana biotechnology: hypoimmune platform might stealth cells
Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expe...
July 9, 2023, 10:09 am